ADReCS

Pharmaceutical Information

Drug Name	Cytarabine
Drug ID	BADD_D00560
Description	A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
Indications and Usage	For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia. Cytarabine is indicated in combination with [daunorubicin] for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.[L32843]
Marketing Status	approved; investigational
ATC Code	L01BC01
DrugBank ID	DB00987
KEGG ID	D00168
MeSH ID	D003561
PubChem ID	6253
TTD Drug ID	D07XSN
NDC Product Code	71288-168; 61703-304; 55512-0026; 25021-229; 61703-319; 68083-343; 71288-108; 12848-1003; 71288-109; 71288-169; 58623-0026; 61703-303; 63323-120; 68083-337; 61703-305; 67430-075; 25021-223
UNII	04079A1RDZ
Synonyms	Cytarabine \| Arabinosylcytosine \| Cytosine Arabinoside \| Arabinoside, Cytosine \| Arabinofuranosylcytosine \| Aracytidine \| beta-Ara C \| beta Ara C \| Cytarabine Hydrochloride \| Cytosar \| Cytosar-U \| Cytosar U \| Ara-C \| Ara C \| Aracytine \| Cytonal

Chemical Information

Molecular Formula	C9H13N3O5
CAS Registry Number	147-94-4
SMILES	C1=CN(C(=O)N=C1N)C2C(C(C(O2)CO)O)O
Chemical Structure

ADRs Induced by Drug

*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..

ADR Term	ADReCS ID	ADR Frequency (FAERS)	ADR Severity Grade (FAERS)	ADR Severity Grade (CTCAE)
Catheter site erythema	23.03.06.014; 12.07.02.003; 08.02.02.003	0.000112%		Not Available
Catheter site pain	12.07.02.004; 08.02.02.004	0.000112%		Not Available
Leukaemia cutis	16.01.03.002; 01.10.03.002	0.000112%		Not Available
Febrile bone marrow aplasia	08.05.02.005; 01.03.03.007	0.000448%		Not Available
Type IV hypersensitivity reaction	10.01.03.022	0.000112%		Not Available
Foetal death	18.01.02.003; 08.04.01.011	0.000112%
Haemorrhage	24.07.01.002	0.001332%		Not Available
Haemorrhage urinary tract	24.07.01.007; 20.02.03.005	0.000112%		Not Available
Pulmonary mass	22.02.07.004	0.000280%		Not Available
Pneumatosis intestinalis	07.11.01.043	0.000224%		Not Available
Toxic skin eruption	23.03.05.003; 10.01.01.008; 12.03.01.073	0.000504%		Not Available
Staphylococcal infection	11.02.05.002	-	-	Not Available
Metabolic disorder	14.11.01.001	0.000112%		Not Available
Pulseless electrical activity	02.03.04.020	0.000168%		Not Available
Cystoid macular oedema	12.02.02.005; 06.04.06.010	0.000112%		Not Available
Nuchal rigidity	17.05.02.006; 15.05.04.005	0.000112%		Not Available
Hypoperfusion	24.06.02.019	0.000168%		Not Available
Oral toxicity	07.05.01.012; 12.03.01.051	0.000112%		Not Available
Intestinal mass	07.11.01.010	0.000112%		Not Available
Gastrointestinal toxicity	12.03.01.019; 07.08.03.006	0.000504%		Not Available
Cerebral vasoconstriction	24.04.06.025; 17.08.02.012	0.000392%		Not Available
Angiopathy	24.03.02.007	0.000112%		Not Available
Epidermal necrosis	23.03.03.035	0.000112%		Not Available
Protein-losing gastroenteropathy	14.03.02.015; 07.11.01.013	0.000112%		Not Available
Skin toxicity	23.03.03.032; 12.03.01.020	0.000112%		Not Available
Adhesion	08.01.03.048	0.000112%		Not Available
Allergic oedema	10.01.03.025; 08.01.07.014	-	-	Not Available
Bacterial infection	11.02.01.005	-	-	Not Available
Haematotoxicity	12.03.01.025; 01.05.01.007	0.000616%		Not Available
Inflammation	10.02.01.089; 08.01.05.007	0.000224%		Not Available

The 11th Page First Pre 11 12 13 14 Next Last Total 14 Pages